Tumor growth fraction in cervical carcinoma

Gynecol Oncol. 1991 Jan;40(1):48-54. doi: 10.1016/0090-8258(91)90085-j.

Abstract

Thirty-one cervical carcinomas have been studied immunohistochemically to determine tumor growth fraction by using the monoclonal antibody Ki-67, which reacts with a nuclear antigen expressed only by proliferating cells. The growth fraction of individual tumor is estimated as the percentage of stained nuclei in a population of 1000 tumor cells. There is a good correlation of the growth fraction measured by Ki-67 with mitotic index and high histological grade of cervical carcinoma. This study, together with that of D. C. Brown, D. Cole, K. C. Gatter, and D. Y. Mason [Brit. J. Cancer 57(2), 178-181 (1988)], shows the usefulness of Ki-67 in the evaluation of growth fraction in cervical carcinoma.

MeSH terms

  • Adenocarcinoma / metabolism
  • Adenocarcinoma / pathology*
  • Adenocarcinoma / ultrastructure
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / immunology
  • Antigens, Surface / immunology
  • Antigens, Surface / metabolism
  • Carcinoma / metabolism
  • Carcinoma / pathology*
  • Carcinoma / ultrastructure
  • Cell Nucleus / immunology
  • Cell Nucleus / metabolism
  • Cell Nucleus / ultrastructure
  • Female
  • Humans
  • Immunohistochemistry
  • Ki-67 Antigen
  • Middle Aged
  • Mitotic Index
  • Neoplasm Staging
  • Uterine Cervical Neoplasms / metabolism
  • Uterine Cervical Neoplasms / pathology*
  • Uterine Cervical Neoplasms / ultrastructure

Substances

  • Antibodies, Monoclonal
  • Antigens, Surface
  • Ki-67 Antigen